{
    "id": 3008,
    "name": "invasive ductal carcinoma",
    "source": "DOID",
    "definition": "A breast ductal carcinoma that is characterized by infiltration into the fibrous or fatty tissue of the breast outside of the duct where it originated. [url:https\\://www.hopkinsmedicine.org/breast_center/breast_cancers_other_conditions/invasive_ductal_carcinoma.html, url:https\\://www.ncbi.nlm.nih.gov/pubmed/25343550]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "3005"
    ],
    "termId": "DOID:3008",
    "evidence": [
        {
            "id": 8822,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast invasive ductal carcinoma cells harboring BRCA1 E23Vfs*17 (also referred to as BRCA1 185delAG) acquired resistance to Rubraca (rucaparib) both in culture and in cell line xenograft models through the expression of a RING-less Brca1 protein utilizing an in-frame translation start site downstream of the mutation (PMID: 27454289).",
            "molecularProfile": {
                "id": 26390,
                "profileName": "BRCA1 E23Vfs*17"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3008,
                "name": "invasive ductal carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6763,
                    "pubMedId": 27454289,
                    "title": "RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27454289"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8823,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast invasive ductal carcinoma cells harboring BRCA1 E23Vfs*17 (also referred to as BRCA1 185delAG) acquired resistance to Platinol (cisplatin) both in culture and in cell line xenograft models through the expression of a RING-less Brca1 protein utilizing an in-frame translation start site downstream of the mutation (PMID: 27454289).",
            "molecularProfile": {
                "id": 26390,
                "profileName": "BRCA1 E23Vfs*17"
            },
            "therapy": {
                "id": 700,
                "therapyName": "Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3008,
                "name": "invasive ductal carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6763,
                    "pubMedId": 27454289,
                    "title": "RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27454289"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02779855",
            "title": "Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7114,
                    "therapyName": "Paclitaxel + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03596073",
            "title": "Topical Calcipotriene Treatment for Breast Cancer Immunoprevention",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3695,
                    "therapyName": "calcipotriene",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03725059",
            "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7723,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6882,
                    "therapyName": "Cyclophosphamide + Epirubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1495,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7722,
                    "therapyName": "Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04129216",
            "title": "The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 794,
                    "therapyName": "Letrozole",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                }
            ]
        }
    ]
}